197 related articles for article (PubMed ID: 37020570)
1. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Ramjee L; Vurgun N; Ngai C; Patel M; Tremblay G
Clinicoecon Outcomes Res; 2023; 15():213-226. PubMed ID: 37020570
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
7. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J; Lafayette R; Kristensen J; Stone A; Cattran D; Floege J; Tesar V; Trimarchi H; Zhang H; Eren N; Paliege A; Rovin BH;
Kidney Int; 2023 Feb; 103(2):391-402. PubMed ID: 36270561
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
[TBL] [Abstract][Full Text] [Related]
9. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non-Small Cell Lung Cancer in Jordan.
Al Rabayah A; Al Froukh R; Sawalha R; Al Shnekat M; Jahn B; Siebert U; Jaddoua SM
Value Health Reg Issues; 2024 Jun; 43():101004. PubMed ID: 38935989
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
Muthukumar M; Desai K; Abogunrin S; Harrower T; Gabriel S; Dinet J
Clinicoecon Outcomes Res; 2017; 9():211-229. PubMed ID: 28458568
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Zhang PF; Xie D; Li Q
Tumori; 2020 Oct; 106(5):400-405. PubMed ID: 32354261
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
Goswami H; Alsumali A; Jiang Y; Schindler M; Duke ER; Cohen J; Briggs A; Puenpatom A
Pharmacoeconomics; 2022 Jul; 40(7):699-714. PubMed ID: 35779197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
